African swine fever virus K205R protein related epitope

By recombinantly expressing ASFV K205R protein and identifying related epitopes, the technical difficulties in the development and detection of African swine fever virus vaccines have been solved, efficient pathogen detection and vaccine development have been achieved, and important technical support for the prevention and control of African swine fever.

CN118878645APending Publication Date: 2024-11-01HENAN AGRICULTURAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410730997.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-06
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

There is a lack of effective commercial vaccines against African swine fever virus (ASFV) in the prior art, and the structural and functional characteristics of ASFV proteins have not been studied in depth, which has affected the effectiveness of vaccine development and virus detection.

Method used

By recombinantly expressing the ASFV K205R protein, screening and identifying relevant epitopes, monoclonal antibodies are prepared, and specific epitopic sites are identified using truncated overlapping peptide technology, thus providing a technical basis for the detection of ASFV and vaccine development.

Benefits of technology

The efficiency of ASFV serological testing and the effectiveness of vaccines have been achieved, important technical means for targeting African swine fever, and laid the foundation for the development of epitope-based diagnostic tools and vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118878645A_ABST
    Figure CN118878645A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of animal epidemic disease prevention and treatment, and particularly relates to an epitope related to African swine fever virus K205R protein. The number of the epitopes is two, wherein the epitope aa is an epitope amino acid sequence from 160 to 170, and the epitope amino acid sequence is PEIQAILDEQF; and the amino acid sequence of the epitope aa 176-183 is IIRLHAEG. In the application, the inventor prepares the related monoclonal antibody by using the ASFV K205R protein prepared by recombination, further truncates the overlapped polypeptide and other technologies, identifies the epitopes recognized by the monoclonal antibody, and can lay a certain technical foundation for more efficient ASFV serological detection and effective African swine fever prevention and treatment vaccine development based on the epitopes. Therefore, the method has good technical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the technical field of animal disease prevention and control, and specifically relates to an epitope related to the K205R protein of the African swine fever virus. Background Art

[0002] African swine fever (ASF) is a highly contagious and fatal hemorrhagic viral disease caused by an African swine fever virus (ASFV). It can infect wild boars and domestic pigs of various ages and breeds. The clinical symptoms are diverse, characterized by high fever and internal bleeding, and the morbidity and mortality rate are as high as 100%. Therefore, ASFV poses a huge threat to the pig farming industry. However, there is no effective commercial vaccine against African swine fever in the prior art.

[0003] African swine fever virus (ASFV) belongs to the genus ASFV of the family Asfrigiviridae. It is an enveloped double-stranded DNA virus with a genome size of approximately 170-193kb, encoding more than 150 open reading frames, and a highly conserved central gene region. It is the only existing DNA arbovirus, and the virus particles have an icosahedral structure. However, the existing technology still lacks in-depth research on the structure and functional characteristics of most ASFV proteins. Some studies have shown that 12 viral proteins in ASFV proteins are the main targets of serological immunity, among which K205R can be detected in the infected cytoplasm 4 hours after infection, and a sustained high serological response to K205R can be observed in the late infection period. In short, although K205R is a non-structural protein, it plays an important role in viral replication, so it can be used as an important target for serological detection of ASFV infection.

[0004] In the immune mechanism, the host will produce an adaptive immune response by recognizing antigenic epitopes to resist the invasion of foreign pathogens. Therefore, accurate epitope analysis is crucial for understanding the immune response and immune protection mechanism and developing epitope-based ASFV diagnostic tools and vaccines. As mentioned above, since ASFV K205R plays an important role in virus replication and serological detection, accurate identification and recognition of epitopes related to the African swine fever virus K205R protein is of great technical significance for the development of African swine fever vaccines. Summary of the invention

[0005] In the present application, the inventors screened, identified and recognized the epitopes related to the African swine fever virus K205R protein by preparing monoclonal clones using recombinantly expressed ASFV K205R protein, thereby laying a certain technical foundation for the detection of ASFV and vaccine development.

[0006] The technical solution adopted in this application is described in detail as follows.

[0007] Epitopes related to the African swine fever virus K205R protein, wherein there are two epitopes: antigenic epitopes aa 160-170 and aa176-183; The amino acid sequence of the antigen epitope aa 160-170 is shown in SEQ ID No. 1, and is as follows: PEIQAILDEQF; The amino acid sequence of the antigen epitope aa 176-183 is shown in SEQ ID No. 2, and is as follows: IERLHAEG.

[0008] The application of the epitope related to the African swine fever virus K205R protein in establishing an ASFV serological detection method.

[0009] The application of the epitope related to the African swine fever virus K205R protein in the preparation of ASFV prevention and treatment vaccines.

[0010] The technical principles of monoclonal antibody preparation and the development of related pathogen detection using monoclonal antibody technology are relatively mature and are commonly used in related pathogen detection and vaccine development and preparation. In this application, based on these prior art principles, the inventors used recombinant ASFV K205R protein to prepare related monoclonal antibodies, and further used truncated overlapping polypeptides and other technologies to identify the epitopes recognized by the monoclonal antibodies. Based on these epitope sites, a certain technical foundation can be laid for more efficient ASFV serological detection and effective African swine fever prevention and control vaccine development, so it has good technical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 These are the relevant experimental results in the process of preparing ASFV K205R recombinant protein; among them: A is the electrophoresis diagram of PCR amplification of ASFV K205R gene; B is the detection result of the eluate at different imidazole concentrations during the purification of ASFV K205R recombinant protein. It can be seen that the target protein was eluted in large quantities at a concentration of 300 Mmol imidazole; Figure 2 The relevant detection and analysis results of the prepared recombinant ASFV K205R protein; wherein: A is the SDS-PAGE electrophoresis detection result of the recombinant ASFV K205R protein; in the figure: M protein marker, 10-180 kDa; lane 1, purified K205R protein; B is the reactivity analysis of K205R protein based on recombinant HIS tag detection using WB method; in the figure: M protein marker, 10-180 kDa; lane 1, purified K205R protein; lane 2, empty pET-28a vector; C is the reactivity of the recombinant ASFV K205R protein with positive serum detected by WB method; in the figure: M protein marker, 10-180 kDa; lane 1, purified K205R protein; lane 2, empty pET-28a vector; Figure 3 These are some experimental results in the process of preparing monoclonal antibodies; among them: A is the serum titer test result of typical mice during the mouse immunization process (based on ELISA method); B is the detection result of the monoclonal antibody against the recombinant K205R protein (WB method); in the figure: lane 1, K205R protein; lane 2, ASFV p30 protein with His tag as a control; C is the IFA test result of monoclonal antibody cell lines 6F5 and 6E2; Figure 4 The identification and detection results of monoclonal antibodies prepared by different hybridoma cell lines (6F5, 6E2); wherein: A is the identification result of the subtype of monoclonal antibodies prepared by different hybridoma cell lines; B is the detection result of purified monoclonal antibody based on SDS-PAGE; in the figure: M protein marker, 10-180kDa; lane 1, monoclonal antibody produced by 6F5 hybridoma cell line; lane 2, monoclonal antibody produced by 6E2 hybridoma cell line; HC and LC are immunoglobulin heavy chain and light chain respectively; C is the titration data of ascites induced by different hybridoma cell lines; Figure 5 Schematic diagram of the truncation process of the full-length recombinant ASFV K205R protein and its truncated fragments during epitope recognition; in the figure: the original complete K205R sequence (206 amino acids) is blue; the fragment that can only be recognized by the monoclonal antibody produced by the 6F5 cell line is highlighted in green; the fragment that can only be recognized by the 6E2 monoclonal antibody is highlighted in orange; the gray part is the part that cannot be recognized by the monoclonal antibodies produced by 6F5 or 6E2; the numbers in the figure represent the positions of amino acids in the K205R protein and the truncated fragment protein; Figure 6 The linear epitope recognition of the monoclonal antibody produced by the 6F5 cell line; A is the amino acid site identified by the first round of truncation (AA138-206); B is the amino acid site identified by the second round of truncation (AA 138-180); C is the amino acid site identified by the third round of truncation (AA 160-180); D is the amino acid site identified by the fourth round of truncation (AA 160-170); Figure 7 The linear epitope recognition of the monoclonal antibody produced by the 6E2 cell line; A is the amino acid site identified by the first round of truncation (AA138-206); B is the amino acid site identified by the second round of truncation (AA 166-206); C is the amino acid site identified by the third round of truncation (AA 166-186); D is the amino acid site identified by the fourth round of truncation (AA 176-183); Figure 8 To analyze the sequence conservation and spatial structural characteristics of the identified epitopes; wherein: A is a multiple sequence alignment of the identified epitope with K205R of other ASFV strains; in the figure: 160PEIQAILDEQF170 is marked with a red box; 176IERLHAEG183 is marked with a blue box; B is the predicted model of the ASFV K205R structure (the left and right pictures are schematic diagrams of the protein tertiary structure); in the picture: the structure of the K205R protein is shown in brown, and 160PEIQAILDEQF170 (red) and 176IERLHAEG183 (blue) are displayed on the surface of the K205R protein structure. DETAILED DESCRIPTION

[0012] The present application is further explained below in conjunction with the embodiments. Before introducing the specific embodiments, some experimental backgrounds in the following embodiments are briefly introduced as follows.

[0013] Biomaterials: ASFV-positive serum was purchased from China Veterinary Culture Collection (Beijing, China); ASFV-negative serum samples (normal porcine serum, as negative control) were purchased from the China Veterinary Drug Administration (Beijing, China); Mouse myeloma cells (SP2 / 0) and pig kidney cells (PK-15) are common and commonly used materials in existing African swine fever prevention and control research or related animal experiments, and can be obtained from public channels. The applicant is a professional research institution, and the inventor has been engaged in related animal disease research for a long time, so the relevant experimental materials have been preserved for a long time; Escherichia coli DH5α and Escherichia coli BL21 (DE3) cells were purchased from Qingke Biotechnology Co., Ltd. (Zhengzhou, China); BALB / c mice were purchased from Zhengzhou Huaxing Experimental Animal Factory (Zhengzhou, China); During the experiment, relevant primer synthesis and gene sequencing were provided by Qingke Biotechnology Co., Ltd. (Zhengzhou, China).

[0014] Example 1 The main technical idea of ​​this application is: first, recombinant expression is used to prepare the ASFV K205R protein, then the protein is used to immunize mice and further screen to obtain the corresponding monoclonal antibodies, and finally, the truncated overlapping polypeptides and other technologies are used to screen and identify specific epitope sites, thereby laying a technical foundation for subsequent efficient pathogen detection and vaccine development. This embodiment first introduces the preparation process of the ASFV K205R recombinant protein as follows.

[0015] (I) Design of primers and PCR amplification to obtain the ASFV K205R gene sequence Based on the determined K205R gene sequence, the inventors further commissioned Qingke Biotechnology Co., Ltd. (Zhengzhou, China) to synthesize and provide the K205R coding region (reference GenBank sequence number MK128995.1).

[0016] Based on the synthetic sequence and in combination with the needs of subsequent expression vectors, Xho I and EcoR I restriction sites were added. To facilitate the preparation of recombinant plasmids, PCR amplification was further performed. During amplification, the specific primer pairs were designed as follows: F: 5'-gtggtggtggtggtggtggtgctcgagCTTCTTCATCATCT-3', R: 5'-gtggtggtggtggtggtggtgctcgagCTTCTTCATCATCT-3'; The electrophoresis results of the amplified products were as follows Figure 1 As shown ( Figure 1 A, the full length of K205R gene is 618 bp), it can be seen that the electrophoresis amplification results are consistent with expectations.

[0017] (II) Construction of recombinant expression plasmid Referring to the conventional operation of existing genetic engineering technology, the pET-28a(+) vector was double-digested with Xho I and EcoR I, the digestion product was recovered, and ligated and recombined with the ASFV K205R gene prepared in step (a) to prepare the recombinant plasmid pET-28a(+)-K205R.

[0018] When connecting the amplified product with the digested plasmid, according to the homologous recombination method, the specific connection system design is as follows: pET-28a(+) vector: Xμl; K205R gene amplification product: Y μl; 5×CEⅡBuffer (Novagen): 4 μl; ExnaseⅡ (Novagen): 2μl; Use a pipette to gently pipette the mixture to mix well, centrifuge briefly to collect the reaction solution at the bottom of the tube, react at 37°C for 30 minutes, and immediately cool on ice for later use; X / Y calculates the amount of vector and insert fragment according to the following formula: Optimal vector dosage = [0.02 × number of base pairs of cloning vector] ng (0.03 pmol); The optimal amount of insert fragment = [0.04 × number of base pairs of insert fragment] ng (0.06 pmol).

[0019] 3. Transformation and Expression When transforming the ligation product, the heat shock method is used. The specific transformation operation is as follows: Add 5 μl of the ligation product to 50 μl of DH5α competent cells thawed on ice, mix well, and place on ice for 30 min; Subsequently, heat shock was performed in a 42°C water bath for 45 s and then immediately cooled on ice for 2 min; Then, add 700 μl of LB medium (without antibiotics) in a clean bench and shake at 37°C and 220 rpm for 1 hour; after the culture is completed, centrifuge the bacterial solution at 4000 rpm for 4 minutes and discard 700 μl of the supernatant; resuspend the bacteria with the remaining culture medium (supernatant), resuspend the bacteria with a sterile coating stick and evenly apply it on LB solid medium containing Kana resistance (100 μg / ml); invert and culture in a 37°C incubator overnight (about 12 hours); Finally, the positive monoclonal colonies were picked and inoculated into 5 mL LB solution containing Kana antibiotics (100 μg / ml) for expansion culture, and then the bacterial solution was further identified by PCR, and the positive bacterial solution was sent to Qingke Biotechnology Co., Ltd. for sequencing. After ensuring that the sequence is correct, the strains containing the correct recombinant plasmids are stored for future use.

[0020] The correct product (i.e., recombinant plasmid) in the above was transformed into Escherichia coli BL21 (DE3) competent cells, and the correct transformed strain was further screened and identified; the correct transformed strain was inoculated into LB medium, cultured to about OD600 = 0.8, IPTG (isopropyl-β-D-thiogalactopyranoside) was added to a final concentration of 0.5 mM, and cultured overnight at 16°C and 180rpm to induce protein supernatant expression.

[0021] (IV) Purification and identification After the induction expression is completed, the culture medium (recombinant ASFV K205R is expressed as soluble protein in the supernatant) is taken and the protein is purified using a nickel-nitrilotriacetic acid metal affinity chromatography column. The relevant process and operation can be referred to as follows: First, use 20% ethanol, ultrapure water, and imidazole-free buffer to elute the column. Subsequently, the sample to be purified (supernatant) was filtered through a 0.22 μm filter membrane and then loaded into the chromatography column; After loading, 20Mmol, 50Mmol, 100Mmol, 300Mmol, and 500Mmol imidazole buffer were used for elution in sequence; Finally, the eluate (i.e., the eluate containing the purified protein) is collected and sampled for detection and analysis.

[0022] In the above process, the relevant reagent formulas are as follows: Buffer without imidazole: 2.24g Tirs, 17.53g Nacl, 50mL glycerol are added to deionized water to dissolve and then the volume is adjusted to 1L; 500Mmol imidazole buffer (20Mmol, 50Mmol, 100Mmol, 300Mmol imidazole buffer can be configured according to this ratio): 2.24g Tirs, 17.53g Nacl, 50mL glycerol, 34.04g imidazole are added to deionized water to dissolve and then the volume is adjusted to 1L.

[0023] After purification, the relevant experimental test results are as follows Figure 1 ( Figure 1 As shown in B), it can be seen that the recombinant ASFV K205R protein can be eluted in large quantities under 300 Mmol imidazole conditions.

[0024] The expressed K205R protein was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Figure 2 ( Figure 2 As shown in A), it can be seen that: except for the target protein, there are very few miscellaneous bands, indicating that the protein purity is high.

[0025] Furthermore, the reactivity of the prepared ASFV K205R protein was detected by Western Blot (WB) method using HIS tag (1:5000) and ASFV positive serum (1:1000 dilution), respectively.

[0026] The results are as follows Figure 2 ( Figure 2 B. Figure 2 C), it can be seen that: using commercial HRP-coupled anti-HIS antibody for incubation, the relevant test results are as follows Figure 2 As shown in B, the protein molecular weight is approximately 33KD, which is consistent with the expected size, and based on ASFV positive serum, the results show that the protein reacts well with the positive serum, indicating that the prepared recombinant K205R protein has good immunogenicity.

[0027] Example 2 Using the purified ASFV K205R protein prepared in Example 1, the inventors immunized animals and prepared relevant monoclonal antibodies. The specific experimental process and results are briefly described as follows.

[0028] (I) Animal Immunization Female BALB / c mice (8 weeks old) were used as experimental animals. The recombinant K205R protein prepared in Example 1 was combined with QuickAntibody TM -Mouse 5W rapid immune adjuvant (BioDragon, Beijing, China) was mixed evenly at a 1:1 (mass ratio) and injected intramuscularly into mice on days 0 and 21, respectively (calculated as K205R protein, 20 μg / mouse); On day 35, tail vein blood was collected from immunized mice, and the antibody titer was determined by enzyme-linked immunosorbent assay (ELISA); The results of mouse serum titer determination are as follows Figure 3 ( Figure 3 As shown in A), it can be seen that the serum titer of mice (M-1 mice) is as high as 1:2048000, which has a good antibody effect, so this mouse was selected for subsequent experiments.

[0029] The mice with the highest serum antibody titer were selected and injected with K205R protein (20 μg) again for booster immunization (only K205R protein was injected). The mice were killed by cervical dislocation 3 days after the booster immunization, and their spleen cells were taken for subsequent experiments.

[0030] (II) Preparation of hybridomas Referring to the conventional operation of the prior art, the mouse spleen cells separated in step (a) were fused with SP2 / 0 myeloma cells; after fusion, the fused cells were inoculated into a 96-well plate at an amount of 200 μl per well, and the hybridoma cells were cultured using HAT (Sigma, St. Louis, USA) medium.

[0031] (III) Screening and validation of monoclonal antibodies The hybridoma cells that can produce immune antibodies to recombinant K205R in step (ii) are detected and screened by ELISA method. The specific ELISA operation process can be referred to as follows: First, the recombinant ASFV K205R protein (diluted to 6 μg / mL in phosphate buffered saline (PBS)) was coated on an ELISA plate overnight at 4°C; after coating, the plate was washed three times with phosphate buffered saline (PBST) containing 0.01% Tween-20; Subsequently, the coated ELISA plate was blocked with PBST containing 5% skim milk for 1 hour at 37°C; after blocking, the plate was washed three times with phosphate buffered saline (PBST) containing 0.01% Tween-20; Then, 100 μL of hybridoma supernatant was added as the primary antibody (SP2 / 0 cell supernatant and mouse positive serum were used as negative and positive controls, respectively), and incubated at 37°C for 1 hour; after the incubation, the cells were washed three times with phosphate buffered saline (PBST) containing 0.01% Tween-20; Then, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG was added as the secondary antibody (Proteintech, Wuhan, China, 1:5000 dilution) and incubated at 37°C for 45 min. After the incubation, the cells were washed three times with phosphate buffered saline containing 0.01% Tween-20 (PBST). Finally, 3,3',5,5'-tetramethylbenzidine (Solarbio, Beijing, China) was added to react for 15 min. After the reaction, 50 μL sulfuric acid (2 M) was added to terminate the reaction and the sample was detected by an enzyme label detector (TECAN, Switzerland) and read the absorbance at 450 nm.

[0032] Based on the absorbance data, hybridoma cell lines that can stably secrete mAbs against ASFV K205R protein were screened with P / N ≥ 2.1 (positive / negative value) as the screening criterion.

[0033] Finally, two cell lines that can stably secrete antibodies specific to K205R were screened and obtained: 6F5 and 6E2. At the same time, the inventors conducted further testing and verification of the prepared monoclonal antibodies (monoclonal antibodies). The specific situation is briefly described as follows.

[0034] (1) Specificity verification based on Western blot analysis When testing and verifying the specificity of the reaction between the prepared monoclonal antibody and the K205R protein, the specific experimental operation process is as follows: First, the K205R protein (prepared in Example 1) was separated by 10% SDS-PAGE and then transferred to a 0.22 μm polyvinylidene fluoride (PVDF) membrane (Millipore, Darmstadt, Germany) for Western blot analysis; Subsequently, the transferred PVDF membrane was immersed in 5% skimmed milk powder for 2 hours for blocking; After blocking, the monoclonal antibody prepared above was used as the primary antibody and incubated overnight at 4°C. After incubation, the membrane was washed three times with PBST; Then, HRP-conjugated goat anti-mouse antibody (1:5000) was used as the secondary antibody and incubated at room temperature for 45 min. After the incubation, the membrane was washed three times with PBST; Finally, the images were visualized using the Amersham Imager 680 Bioanalytical Imaging System (Cytiva, Marlborough, Massachusetts, USA).

[0035] The experimental results of monoclonal antibodies prepared based on different hybridoma cell lines (6F5, 6E2) are as follows Figure 3 ( Figure 3 As shown in B), it can be seen that the prepared monoclonal antibody can specifically react with the recombinant K205R protein (antigen), but will not react with other antigen proteins (ASFV p30).

[0036] (2) Specific detection based on IFA (indirect immunofluorescence assay) First, referring to the above description and conventional operations in the prior art, a recombinant expression plasmid vector with K205R gene was constructed: pCMV-3×Flag-K205R; Subsequently, pCMV-3×Flag-K205R plasmid and pCMV-3xFlag empty vector plasmid (used as negative control) were transfected into PK-15 cells, and the medium was changed 8 h after transfection. The medium was discarded 24 h after transfection, and the cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) at room temperature for 30 min and permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 15 min; After permeabilization, the sections were washed three times with PBS and then blocked with 5% bovine serum albumin (BSA) diluted in PBS at room temperature for 1 h; After blocking, the cells were washed three times with PBS, and then the hybridoma supernatant was added as the primary antibody, and the cells were incubated at room temperature for 1 h; after incubation, the cells were washed with PBS, and then mouse fluorescein isothiocyanate dye was used as the secondary antibody (Proteintech, Wuhan, China, 1:500) for 1 h at room temperature in the dark; After incubation, the cells were washed four times with PBS and incubated with 4;6-diamidino-2-phenylindole (DAPI, Solarbio, Beijing, China) for 10 min; After incubation, the cells were washed with PBS, and fluorescence images were captured using an inverted fluorescence microscope (Olympus, IX73, Tokyo, Japan).

[0037] The IFA image results are as follows Figure 3 As shown ( Figure 3C), analysis showed that: there was no green fluorescence in PK-15 cells transfected with the empty vector, indicating that the K205R protein was not expressed in the cells, while green fluorescence was observed in cells transfected with K205R, indicating that the monoclonal antibody secreted by the hybridoma cell lines (6F5, 6E2) could specifically recognize the K205R protein expressed in PK-15 cells.

[0038] (IV) Preparation and Detection Validation of Monoclonal Antibody Ascites The monoclonal antibodies were subtyped using a mouse mAb subtype identification kit (Proteintech, Wuhan, China); the results are shown in Figure 4 As shown ( Figure 4 A) The heavy chain subclasses of monoclonal antibodies produced by 6F5 and 6E2 cell lines are IgG2a and IgG1, respectively, but their light chains are both kappa.

[0039] To obtain ascites of monoclonal antibodies, 8-week-old female BALB / c mice were first pretreated with 500 μL of sterile liquid paraffin. After 7 days, positive hybridoma cells (6F5, 6E2) were injected intraperitoneally. After 7 days, ascites were collected and purified mAbs were prepared by Protein G affinity chromatography based on the results of isotype determination.

[0040] The antibody purification results were further identified by SDS-PAGE (and stained with Coomassie Brilliant Blue), where ( Figure 4 B): The IgG heavy chain (HC) and light chain (LC) bands are 50kDa and 25kDa respectively, and there are no other mixed bands, indicating high purity.

[0041] Subsequently, the antibody titer of ascites was measured by indirect ELISA. The results showed that the titer of monoclonal antibodies produced by 6F5 and 6E2 cell lines could reach 1:2,048,000 ( Figure 4 C), indicating a high antibody titer.

[0042] Example 3 In order to determine the smallest linear epitope, the inventors used Western blotting to determine the smallest linear epitope that can be recognized by the cloned antibody by truncating the sequence. The specific experimental process is as follows.

[0043] First, referring to the conventional operation in the prior art, primers were designed based on the truncated sequence and PCR amplification was performed; Subsequently, the truncated sequences were recombined into the PGEX-6P-1 plasmid vector using homologous recombination; Then, the recombinant plasmid containing the truncated sequence was transformed into Escherichia coli BL21 (DE3) by heat shock method, and the positive clones with correct transformation were screened and cultured. When the OD600 was about 0.8, IPTG with a final concentration of 0.5M was added to induce expression to obtain GST fusion protein (induced at 37°C and 220rpm for 4-6 hours); after the induction expression was completed, the bacterial solution was sampled for SDS-PAGE electrophoresis detection and identification to ensure correct expression; Finally, the truncated proteins expressed correctly after the above identification were identified using WB technology using peroxidase-coupled anti-GST antibody (as a positive control, Proteintech, 1:5000) and the two monoclonal antibodies prepared in Example 2 above.

[0044] The schematic diagram of the overall truncation recognition process is as follows Figure 5 During the truncation process, the complete ASFV K205R protein was truncated into three overlapping fragments: aa 1-72, aa 68-142, and aa 138-206, and four rounds of overlapping short peptides spanning the full length of the K205R protein were designed. The test results of different hybridoma cell lines (6F5 and 6E2) are shown in Figure 6 , Figure 7 shown.

[0045] Finally, after four rounds of truncation experiments, the smallest epitope that can be recognized by the monoclonal antibody was obtained, namely: For the monoclonal antibody against the 6F5 hybridoma cell line, the antigen epitope aa 160-170: PEIQAILDEQF is the smallest linear epitope bound by the antibody; For the monoclonal antibody against 6E2 hybridoma cell line, the antigen epitope aa 176-183: IERLHAEG is the smallest linear epitope bound by the antibody.

[0046] For the identified minimal epitope, in order to examine its conservation degree in different ASFV genotypes, the inventors compared it with the sequences of 16 typical ASFV strains in the prior art, and used relevant software to predict and analyze the tertiary spatial binding of the epitope peptide with the K205R protein. Figure 8 shown.

[0047] Analysis shows that 160PEIQAILDEQF170 and 176IERLHAEG183 are highly conserved among the 16 ASFV strains at home and abroad, do not contain mutation sites, and have a sequence similarity of 100%; the tertiary structure analysis shows that the epitope is located on the surface of the K205R protein, which has partial α-helical turns and coiled regions, exhibiting a strong antigenic index and being easily recognized by antibodies, and is therefore expected to play a greater role in subsequent virus detection and vaccine preparation.

Claims

1. An epitope associated with the African swine fever virus K205R protein, characterized in that: There are two epitopes: antigenic epitopes aa160-170 and aa 176-183; The amino acid sequence of epitope aa 160-170 is shown in SEQ ID No. 1 and is as follows: PEIQAILDEQF; The amino acid sequence of epitope aa 176-183 is shown in SEQ ID No. 2, and is as follows: IERLHAEG.

2. Application of the epitope related to the African swine fever virus K205R protein according to claim 1 in establishing an ASFV serological detection method.

3. Use of the epitope related to the African swine fever virus K205R protein according to claim 2 in the preparation of ASFV prevention and control vaccines.